Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study


Gunaldi M., Duman B. B. , Afsar C. U. , PAYDAŞ S. , Erkisi M., KARA İ. O. , ...Daha Fazla

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, cilt.22, ss.242-247, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 22 Konu: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1177/1078155214567162
  • Dergi Adı: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Sayfa Sayıları: ss.242-247

Özet

Background: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic.